» Articles » PMID: 33939061

Brain Energy Deficit As a Source of Oxidative Stress in Migraine: A Molecular Basis for Migraine Susceptibility

Overview
Journal Neurochem Res
Specialties Chemistry
Neurology
Date 2021 May 3
PMID 33939061
Citations 28
Authors
Affiliations
Soon will be listed here.
Abstract

People with migraine are prone to a brain energy deficit between attacks, through increased energy demand (hyperexcitable brain) or decreased supply (mitochondrial impairment). However, it is uncertain how this precipitates an acute attack. Here, the central role of oxidative stress is adduced. Specifically, neurons' antioxidant defenses rest ultimately on internally generated NADPH (reduced nicotinamide adenine dinucleotide phosphate), whose levels are tightly coupled to energy production. Mitochondrial NADPH is produced primarily by enzymes involved in energy generation, including isocitrate dehydrogenase of the Krebs (tricarboxylic acid) cycle; and an enzyme, nicotinamide nucleotide transhydrogenase (NNT), that depends on the Krebs cycle and oxidative phosphorylation to function, and that works in reverse, consuming antioxidants, when energy generation fails. In migraine aura, cortical spreading depression (CSD) causes an initial severe drop in level of NADH (reduced nicotinamide adenine dinucleotide), causing NNT to impair antioxidant defense. This is followed by functional hypoxia and a rebound in NADH, in which the electron transport chain overproduces oxidants. In migraine without aura, a similar biphasic fluctuation in NADH very likely generates oxidants in cortical regions farthest from capillaries and penetrating arterioles. Thus, the perturbations in brain energy demand and/or production seen in migraine are likely sufficient to cause oxidative stress, triggering an attack through oxidant-sensing nociceptive ion channels. Implications are discussed for the development of new classes of migraine preventives, for the current use of C57BL/6J mice (which lack NNT) in preclinical studies of migraine, for how a microembolism initiates CSD, and for how CSD can trigger a migraine.

Citing Articles

The effects of concurrent alpha-linolenic acid, L-carnitine supplementation on clinical symptoms, mental health, and quality of life in women with migraine: a randomized, triple-blind, placebo-controlled trial.

Golpour-Hamedani S, Bagherniya M, Khorvash F, Feizi A, Sharma M, Askari G Nutr J. 2025; 24(1):40.

PMID: 40082970 PMC: 11905556. DOI: 10.1186/s12937-025-01107-7.


Bridging Gaps in Migraine Management: A Comprehensive Review of Conventional Treatments, Natural Supplements, Complementary Therapies, and Lifestyle Modifications.

Abo-Elghiet F, Elosaily H, Hussein D, El-Shiekh R, Aaqoulah A, Yousef E Pharmaceuticals (Basel). 2025; 18(2).

PMID: 40005953 PMC: 11858087. DOI: 10.3390/ph18020139.


Sexual Dimorphism in Migraine. Focus on Mitochondria.

Fila M, Przyslo L, Derwich M, Pawlowska E, Blasiak J Curr Pain Headache Rep. 2025; 29(1):11.

PMID: 39760955 DOI: 10.1007/s11916-024-01317-4.


Practical supplements for prevention and management of migraine attacks: a narrative review.

Hajhashemy Z, Golpour-Hamedani S, Eshaghian N, Sadeghi O, Khorvash F, Askari G Front Nutr. 2024; 11:1433390.

PMID: 39539367 PMC: 11557489. DOI: 10.3389/fnut.2024.1433390.


Association between serum folate levels and migraine or severe headaches: A nationwide cross-sectional study.

Luwen H, Ping C, Qing-Rong O, Lei X, Linlin L, Yu M Medicine (Baltimore). 2024; 103(45):e40458.

PMID: 39533580 PMC: 11557034. DOI: 10.1097/MD.0000000000040458.


References
1.
Graham J . Migraine, quo vadis?. Headache. 1988; 28(10):681-8. DOI: 10.1111/j.1526-4610.1988.hed2810681.x. View

2.
Buse D, Loder E, Gorman J, Stewart W, Reed M, Fanning K . Sex differences in the prevalence, symptoms, and associated features of migraine, probable migraine and other severe headache: results of the American Migraine Prevalence and Prevention (AMPP) Study. Headache. 2013; 53(8):1278-99. DOI: 10.1111/head.12150. View

3.
Hu X, Markson L, Lipton R, Stewart W, Berger M . Burden of migraine in the United States: disability and economic costs. Arch Intern Med. 1999; 159(8):813-8. DOI: 10.1001/archinte.159.8.813. View

4.
Gross E, Lisicki M, Fischer D, Sandor P, Schoenen J . The metabolic face of migraine - from pathophysiology to treatment. Nat Rev Neurol. 2019; 15(11):627-643. DOI: 10.1038/s41582-019-0255-4. View

5.
Borkum J . Migraine Triggers and Oxidative Stress: A Narrative Review and Synthesis. Headache. 2015; 56(1):12-35. DOI: 10.1111/head.12725. View